Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1984 2
1985 11
1986 10
1987 31
1988 25
1989 30
1990 20
1991 28
1992 34
1993 21
1994 33
1995 40
1996 17
1997 11
1998 17
1999 12
2000 8
2001 11
2002 10
2003 11
2004 13
2005 30
2006 15
2007 13
2008 6
2009 10
2010 10
2011 11
2012 11
2013 11
2014 10
2015 11
2016 5
2017 7
2018 2
2019 6
2020 3
2021 5
2022 4
2023 4
2024 6
2025 11
2026 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

561 results

Results by year

Filters applied: . Clear all
Page 1
Pharmacokinetics of famotidine in infants.
Wenning LA, Murphy MG, James LP, Blumer JL, Marshall JD, Baier J, Scheimann AO, Panebianco DL, Zhong L, Eisenhandler R, Yeh KC, Kearns GL. Wenning LA, et al. Clin Pharmacokinet. 2005;44(4):395-406. doi: 10.2165/00003088-200544040-00004. Clin Pharmacokinet. 2005. PMID: 15828852 Clinical Trial.
BACKGROUND: Although famotidine pharmacokinetics are similar in adults and children older than 1 year of age, they differ in neonates owing to developmental immaturity in renal function. Little is currently known about the pharmacokinetics of famotidine in infants a …
BACKGROUND: Although famotidine pharmacokinetics are similar in adults and children older than 1 year of age, they differ in neonates …
Evaluation of the Efficacy and Safety of a Dual Delayed-Release Formulation of 10-mg Esomeprazole in Patients with Gastric Erosions: A Multicenter, Randomized, Double-Blind, Active-Control, Phase III Study.
Lim H, Lee JY, Kwon YH, Moon HS, Park JK, Kim KB, Kim SW, Youn YH, Kim SG, Kim GH, Kim JW, Jang JY, Kwon KS, Kwon JG, Kim HS, Hong SJ, Lee KJ, Choi SC, Moon JS, Kim N, Park JJ, Lim Y, Hong SH, Jung HY. Lim H, et al. Gut Liver. 2025 Jul 15;19(4):519-527. doi: 10.5009/gnl240390. Epub 2025 Feb 14. Gut Liver. 2025. PMID: 39949051 Free PMC article. Clinical Trial.
Therefore, this study compared the efficacy and safety of HIP2101 and 20-mg famotidine (RLD2101) in patients with gastric erosions. METHODS: In this multicenter, randomized, double-blind, active-control, phase III study, 326 patients with endoscopically proven gastric muco …
Therefore, this study compared the efficacy and safety of HIP2101 and 20-mg famotidine (RLD2101) in patients with gastric erosions. M …
Harnessing metabolomics and proteomics in a clinical trial for pulmonary arterial hypertension: insights from post-hoc analysis of the REHAB-PH trial.
Pi H, Xia L, Rayner SG, Probstfield JL, Branch KR, Shojaie A, Leary PJ, Gharib SA. Pi H, et al. EBioMedicine. 2026 Apr;126:106191. doi: 10.1016/j.ebiom.2026.106191. Epub 2026 Mar 17. EBioMedicine. 2026. PMID: 41849831 Free PMC article. Clinical Trial.
Linear regression models adjusting for age, sex, body mass index and PAH aetiology evaluated famotidine's molecular effects. False discovery rate was controlled for multiple comparisons. ...At 24 weeks, 34 and 37 participants remained in the famotidine and placebo g …
Linear regression models adjusting for age, sex, body mass index and PAH aetiology evaluated famotidine's molecular effects. False di …
A randomized clinical trial comparing the efficacy of ranitidine and famotidine on intragastric acidity in critically ill pediatric patients.
Aanpreung P, Vanprapar N, Susiva C, Parkpreaw C, Boonyachart C. Aanpreung P, et al. J Med Assoc Thai. 1998 Mar;81(3):185-9. J Med Assoc Thai. 1998. PMID: 9623009 Clinical Trial.
Three cases in the famotidine group had successful prophylaxis with total time pH > or = 4 more than 80 per cent. Famotidine appeared to have a trend toward increasing intragastric pH in critically ill pediatric patients....
Three cases in the famotidine group had successful prophylaxis with total time pH > or = 4 more than 80 per cent. Famotidine …
Effect of Famotidine on Outcomes in Pulmonary Arterial Hypertension: A Randomized Controlled Trial.
Leary PJ, Rayner SG, Branch KRH, Hogl L, Liston NM, Barros LM, Prout J, Nolley S, Buber J, Ralph DD, Probstfield JL. Leary PJ, et al. Chest. 2025 Jul;168(1):189-199. doi: 10.1016/j.chest.2024.12.029. Epub 2025 Jan 4. Chest. 2025. PMID: 39761829 Free PMC article. Clinical Trial.
STUDY DESIGN AND METHODS: We conducted a 24-week, single-center, 1:1 randomized, double-masked, placebo-controlled trial of the H(2)-receptor antagonist famotidine in patients with a diagnosis of PAH. The primary outcome was change in 6-minute walk distance (6MWD) at 24 we …
STUDY DESIGN AND METHODS: We conducted a 24-week, single-center, 1:1 randomized, double-masked, placebo-controlled trial of the H(2)-recepto …
Oral famotidine versus placebo in non-hospitalised patients with COVID-19: a randomised, double-blind, data-intense, phase 2 clinical trial.
Brennan CM, Nadella S, Zhao X, Dima RJ, Jordan-Martin N, Demestichas BR, Kleeman SO, Ferrer M, von Gablenz EC, Mourikis N, Rubin ME, Adnani H, Lee H, Ha T, Prum S, Schleicher CB, Fox SS, Ryan MG, Pili C, Goldberg G, Crawford JM, Goodwin S, Zhang X, Preall JB, Costa ASH, Conigliaro J, Masci JR, Yang J, Tuveson DA, Tracey KJ, Janowitz T. Brennan CM, et al. Gut. 2022 May;71(5):879-888. doi: 10.1136/gutjnl-2022-326952. Epub 2022 Feb 10. Gut. 2022. PMID: 35144974 Free PMC article. Clinical Trial.
OBJECTIVE: We assessed whether famotidine improved inflammation and symptomatic recovery in outpatients with mild to moderate COVID-19. ...Five self-limiting adverse events occurred (famotidine, n=2 (40%); placebo, n=3 (60%)). On day 7, fewer patients on famotidi …
OBJECTIVE: We assessed whether famotidine improved inflammation and symptomatic recovery in outpatients with mild to moderate COVID-1 …
Safety and Tolerability of Multimodal Therapy (Ivermectin, Doxycycline, Vitamin C, Vitamin D, and Zinc) With or Without Famotidine in Australian Patients With COVID-19 Infection: A Pilot Cohort Trial.
McLindon LA, Ried K, Wauchope B, Murnane L, Harradine E, Seman J. McLindon LA, et al. Am J Ther. 2026 Mar-Apr 01;33(2):e121-e131. doi: 10.1097/MJT.0000000000002118. Epub 2026 Feb 13. Am J Ther. 2026. PMID: 41693032 Free PMC article. Clinical Trial.
The multimodal therapy of ivermectin, doxycyline, zinc, vitamin C, and vitamin D 3 was given as core therapy (group-1), or core therapy plus famotidine (group-2) for 10 days in a randomized masked controlled fashion. MEASURES AND OUTCOMES: A total of 275 participants, who …
The multimodal therapy of ivermectin, doxycyline, zinc, vitamin C, and vitamin D 3 was given as core therapy (group-1), or core therapy plus …
Pharmacokinetics and pharmacodynamics of famotidine and ranitidine in critically ill children.
Madani S, Kauffman R, Simpson P, Lehr VT, Lai ML, Sarniak A, Tolia V. Madani S, et al. J Clin Pharmacol. 2014 Feb;54(2):201-5. doi: 10.1002/jcph.219. Epub 2013 Nov 20. J Clin Pharmacol. 2014. PMID: 24258773 Free article. Clinical Trial.
Twenty-four children randomized to either famotidine (n = 12) or ranitidine (n = 12). Sixteen out of twenty-four completed both PK and PD study arms (7/12 famotidine; 4.7 3.4 years; 9/12 ranitidine; 6.6 4.7 years; p = 0.38). ...Ratio of AUC pH to AUC drug concen …
Twenty-four children randomized to either famotidine (n = 12) or ranitidine (n = 12). Sixteen out of twenty-four completed both PK an …
Effectiveness of oral famotidine in reducing the hematologic complications of radiotherapy in patients with esophageal and cardia cancers: a randomized controlled trial.
Rostami M, Yelghi O, Moghaddam ZK, Zeraatchi A, Rezaeejam H, Sadeghi A. Rostami M, et al. Radiat Oncol. 2023 May 20;18(1):83. doi: 10.1186/s13014-023-02281-w. Radiat Oncol. 2023. PMID: 37210511 Free PMC article. Clinical Trial.

RESULTS: The findings indicated a significant effect of famotidine on reduction of thrombocytopenia among intervention group compared to control group (P < 0.0001). ...The lymphocyte (P = 0.007) and platelet (P = 0.004) counts were also significantly greater in famot

…
RESULTS: The findings indicated a significant effect of famotidine on reduction of thrombocytopenia among intervention group compared …
Famotidine in the treatment of gastritis.
Miwa T, Miyoshi A. Miwa T, et al. Scand J Gastroenterol Suppl. 1987;134:46-50. doi: 10.3109/00365528709090140. Scand J Gastroenterol Suppl. 1987. PMID: 2889258 Clinical Trial.
A multicenter, double-blind, comparative trial was conducted to determine the effects of famotidine, a new H2-receptor antagonist, for such lesions. Patients received one of three oral doses (5, 10, or 20 mg) of famotidine twice daily for 2 weeks. ...Symptoms, inclu …
A multicenter, double-blind, comparative trial was conducted to determine the effects of famotidine, a new H2-receptor antagonist, fo …
561 results